HLN1N Stock Chart & Stats
$171.00
$0.00(0.00%)
At close: 4:00 PM EDT
$171.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$150.00 - $205.80
Previous CloseN/A
Volume63.00
Average Volume (3M)0.00
Market Cap
$692.74B
Enterprise Value$51.55B
Total Cash (Recent Filing)$821.01M
Total Debt (Recent Filing)$8.20B
Price to Earnings (P/E)18.1
Beta-0.14
Next Earnings
Mar 04, 2027EPS Estimate
5.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding4,398,289,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio17.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$212.49Price Target Upside24.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)10.19
Revenue Forecast (FY)$275.53B
Bulls Say, Bears Say
Bulls Say
Expanding ProfitabilityHaleon is converting its branded portfolio into stronger earnings, with broad margin expansion indicating benefits from mix, scale, and productivity. If sustained, higher profitability can fund marketing and innovation while improving resilience against pricing pressure and category volatility.
Healthy Cash ConversionCash generation closely tracking earnings supports the quality of Haleon’s reported profits and provides internally generated funding for brand investment, debt service, and shareholder returns. The large 2025 increase further strengthens financial flexibility, despite some historical volatility.
Strong Oral-care Brand MomentumGrowth across multiple oral-care brands demonstrates durable consumer demand in a repeat-purchase category and supports Haleon’s competitive position in everyday health. Broad brand momentum also gives the company a stronger base for innovation, distribution gains, and sustained investment.
Bears Say
Meaningful Debt BurdenAlthough leverage improved, the remaining debt load can constrain capital allocation and absorb cash that could otherwise support innovation, marketing, or shareholder returns. A slower growth environment would make deleveraging and refinancing discipline more important over the medium term.
Recent Top-line SoftnessRecent revenue weakness tempers the durability of Haleon’s margin-led earnings progress and suggests that profitability gains are not yet being supported by consistent broad-based expansion. Persistently soft sales could limit operating leverage and increase pressure on investment efficiency.
Respiratory Category WeaknessWeakness in respiratory products creates a structural drag within an important OTC category, particularly where cough-and-cold demand and Smoker’s Health trends remain subdued. Continued declines could offset strength elsewhere and require greater marketing or innovation investment to restore momentum.
Haleon PLC Sponsored ADR News
HLN1N FAQ
What was Haleon PLC Sponsored ADR’s price range in the past 12 months?
Haleon PLC Sponsored ADR lowest stock price was $150.00 and its highest was $205.80 in the past 12 months.
What is Haleon PLC Sponsored ADR’s market cap?
Haleon PLC Sponsored ADR’s market cap is $692.74B.
When is Haleon PLC Sponsored ADR’s upcoming earnings report date?
Haleon PLC Sponsored ADR’s upcoming earnings report date is Mar 04, 2027 which is in 150 days.
How were Haleon PLC Sponsored ADR’s earnings last quarter?
Haleon PLC Sponsored ADR released its earnings results on Jul 30, 2026. The company reported $2.109 earnings per share for the quarter, missing the consensus estimate of $2.345 by -$0.236.
Is Haleon PLC Sponsored ADR overvalued?
According to Wall Street analysts Haleon PLC Sponsored ADR’s price is currently Undervalued.
Does Haleon PLC Sponsored ADR pay dividends?
Haleon PLC Sponsored ADR does not currently pay dividends.
What is Haleon PLC Sponsored ADR’s EPS estimate?
Haleon PLC Sponsored ADR’s EPS estimate is 5.2.
How many shares outstanding does Haleon PLC Sponsored ADR have?
Haleon PLC Sponsored ADR has 4,398,289,000 shares outstanding.
What happened to Haleon PLC Sponsored ADR’s price movement after its last earnings report?
Haleon PLC Sponsored ADR reported an EPS of $2.109 in its last earnings report, missing expectations of $2.345. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Haleon PLC Sponsored ADR?
Currently, no hedge funds are holding shares in MX:HLN1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haleon PLC Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$212.49 (24.26% Upside)
$212.49 (24.26% Upside)
Blogger Sentiment
Neutral
MX:HLN1N Sentiment 67%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.99%
12-Months-Change
Fundamentals
Return on Equity
2.12%
Trailing 12-Months
Asset Growth
-0.85%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Haleon PLC Sponsored ADR
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
HLN1N Company Deck
HLN1N Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed more positive than negative developments: solid organic growth (3.1%) with sequential improvement, robust margin expansion (gross margin +140 bps; operating margin +120 bps), strong region/product performances (Oral Care, China, India, emerging markets) and continued investment behind digital and innovation. Key headwinds—weak Respiratory (notably cough & cold), regional softness in Europe and the Middle East, and some pricing pressure in Asia—are material but portrayed as cyclical or manageable through productivity and targeted reinvestment. Management maintained guidance (3%–5% organic growth) and expressed confidence in a stronger H2.View all MX:HLN1N earnings summariesHLN1N Stock 12 Month Forecast
Average Price Target
$212.49
▲(24.26% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva
―
Amneal Pharmaceuticals
―